1. Home
  2. PFBC vs EVO Comparison

PFBC vs EVO Comparison

Compare PFBC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Preferred Bank

PFBC

Preferred Bank

N/A

Current Price

$103.55

Market Cap

1.3B

Sector

Finance

ML Signal

N/A

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$1.95

Market Cap

778.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PFBC
EVO
Founded
1991
1993
Country
United States
Germany
Employees
324
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
778.3M
IPO Year
N/A
2007

Fundamental Metrics

Financial Performance
Metric
PFBC
EVO
Price
$103.55
$1.95
Analyst Decision
Hold
Strong Buy
Analyst Count
3
1
Target Price
$102.67
$7.00
AVG Volume (30 Days)
62.8K
41.3K
Earning Date
04-22-2026
04-08-2026
Dividend Yield
3.41%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$2.94
$1.37
Revenue Next Year
$8.31
$10.05
P/E Ratio
$8.85
N/A
Revenue Growth
N/A
N/A
52 Week Low
$81.50
$1.87
52 Week High
$112.26
$4.27

Technical Indicators

Market Signals
Indicator
PFBC
EVO
Relative Strength Index (RSI) 43.03 41.80
Support Level $99.20 $1.90
Resistance Level $109.26 $2.20
Average True Range (ATR) 1.83 0.05
MACD -0.46 0.01
Stochastic Oscillator 19.95 21.21

Price Performance

Historical Comparison
PFBC
EVO

About PFBC Preferred Bank

Preferred Bank is a commercial bank located in California. Its products and services are divided into Personal Banking, Business Banking, and Commercial Banking, which include Checking accounts, Savings accounts, CDs, Loans and Credit, Electronic banking, and Treasury Management. It provides personalized deposit services, real estate finance, commercial loans, and trade finance credit facilities to small and mid-sized businesses and their owners, entrepreneurs, real estate developers and investors, professionals, and high-net-worth individuals.

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: